RDAF 2022 General Assembly Meeting

    21 Mar, 2022

    On 21 March 2022, the Rare Disease Action Forum (RDAF) held its annual General Assembly meeting. An overview of the RDAF’s activities in 2021 and an outlook for 2022 were presented. The RDAF President welcomed the new members and underlined that the collaborative approach, which constitutes the core of the RDAF, is essential to identify barriers, raise awareness and work towards an improved framework for rare diseases.

    The General Assembly elected the RDAF Board of Directors: Shayesteh Fürst-Ladani (SFL Pharma), Jasmin Barman-Aksözen (Swiss Society for Porphyria), Rea Lal (Pfizer), Bettina Nauli (Alexion), Jacqueline de Sá (ProRaris), Alessandro Strebel (Roche), Andreas Uttenweiler (Takeda) and Raffaella Willmann (FSRMM). Shayesteh Fürst-Ladani was re-elected as RDAF President.

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...